- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Alnylam Pharmaceuticals Inc(ALNY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ALNY
11/20/2026: ALNY (1-star) is currently NOT-A-BUY. Pass it for now.
Alnylam Pharmaceuticals is a commercial-stage biotechnology enterprise pioneering RNA interference (RNAi) therapeutics to treat rare and genetically defined diseases. The company exhibits strong operational execution, backed by a validated proprietary delivery platform and a growing portfolio of approved specialty drugs such as Amvuttra and Onpattro. Its primary growth narrative centers on expanding label indications into high-prevalence cardiovascular conditions like ATTR cardiomyopathy. However, risks remain regarding high R&D reinvestment requirements, intensive competitive pressures from alternative genetic modalities, and complex global reimbursement hurdles. The stock suits growth-oriented investors willing to navigate biotechnology sector volatility while monitoring clinical trial readouts and regulatory milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Alnylam offers robust top-line product revenue growth driven by an expanding portfolio of rare disease therapies. |
| Momentum investor | Mixed fit | Momentum fit is conditional on positive near-term clinical readouts and regulatory catalysts. |
| Value investor | Weak fit | The company trades at high valuation multiples based on future growth expectations rather than current earnings. |
| Dividend investor | Weak fit | Alnylam does not pay dividends, prioritizing capital reinvestment for pipeline expansion. |
| Low-risk investor | Weak fit | Biotechnology sector volatility and clinical trial execution risks present higher risk profiles unsuited for conservative investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks frequently experience sharp price movements driven by binary clinical trial results and regulatory decisions. |
| Valuation risk | Medium / high | High expectations are priced into shares, leaving little margin for error if clinical or commercial milestones slip. |
| Competition risk (Antisense and gene-editing competition) | Medium / high | Rapid advancements by competitors using alternative genetic platforms threaten long-term market share. |
| Business quality | Strong | Alnylam possesses a leading intellectual property portfolio and validated commercial franchise in RNAi therapeutics. |
| Dividend income | Low / none | No dividend is paid, offering zero income return for investors. |
| Execution risk | High | Success relies heavily on timely clinical trial readouts, regulatory approvals, and global commercial execution. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 19.80B USD | Price to earnings Ratio 7.47 | 1Y Target Price 284.96 |
Price to earnings Ratio 7.47 | 1Y Target Price 284.96 | ||
Volume (30-day avg) 2.8M shares | Beta 0.44 | 52 Weeks Range 143.40 - 479.79 | Updated Date 11/20/2026 |
52 Weeks Range 143.40 - 479.79 | Updated Date 11/20/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 19.8 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 61.0%
- Active BUY / eligible
- 64 / 105
- 30-Day BUY Count Change
- +16
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 44.7%
- Active BUY / eligible
- 17 / 38
- 30-Day BUY Count Change
- +9
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit 68.96% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Direct commercial sales of approved RNAi medicines including Amvuttra, Onpattro, Givlaari, and Oxlumo. | This is the core engine driving Alnylam's top-line revenue growth. |
| Collaborations and Royalties | Milestone payments, research funding, and royalties from partners like Novartis for partnered drugs such as Leqvio. | Provides non-dilutive capital and validation from major pharmaceutical entities. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When Before Market | Estimate 1.46 | Actual 15.72 |
Profitability
Profit Margin 52.85% | Operating Margin (TTM) 19.5% |
Management Effectiveness
Return on Assets (TTM) 9.51% | Return on Equity (TTM) 138.07% |
Valuation
Trailing PE 7.47 | Forward PE 11.68 | Enterprise Value 17.69B | Price to Sales(TTM) 3.95 |
Enterprise Value 17.69B | Price to Sales(TTM) 3.95 | ||
Enterprise Value to Revenue 3.53 | Enterprise Value to EBITDA 15.54 | Shares Outstanding 133.94M | Shares Floating 133.64M |
Shares Outstanding 133.94M | Shares Floating 133.64M | ||
Percent Insiders 0.2 | Percent Institutions 105.73 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

